These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 35439360

  • 1. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
    Urowitz MB, Aranow C, Asukai Y, Bass DL, Bruce IN, Chauhan D, Dall'Era M, Furie R, Fox NL, Gilbride JA, Hammer A, Ginzler EM, Gonzalez-Rivera T, Levy RA, Merrill JT, Quasny H, Roth DA, Stohl W, van Vollenhoven R, Wallace DJ, Petri M.
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1822-1828. PubMed ID: 35439360
    [Abstract] [Full Text] [Related]

  • 2. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 3. 10 Years of belimumab experience: What have we learnt?
    Levy RA, Gonzalez-Rivera T, Khamashta M, Fox NL, Jones-Leone A, Rubin B, Burriss SW, Gairy K, Maurik AV, Roth DA.
    Lupus; 2021 Oct; 30(11):1705-1721. PubMed ID: 34238087
    [Abstract] [Full Text] [Related]

  • 4. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study.
    Urowitz MB, Ohsfeldt RL, Wielage RC, Dever JJ, Zakerifar M, Asukai Y, Ramachandran S, Joshi AV.
    Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33051264
    [Abstract] [Full Text] [Related]

  • 5. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG, Fusco BE.
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
    van Schaik M, Arends EJ, Soonawala D, van Ommen E, de Leeuw K, Limper M, van Paassen P, Huizinga TWJ, Toes REM, van Kooten C, Rotmans JI, Rabelink TJ, Teng YKO.
    Trials; 2022 Nov 12; 23(1):939. PubMed ID: 36371234
    [Abstract] [Full Text] [Related]

  • 7. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP, D'Cruz DP.
    Expert Opin Drug Metab Toxicol; 2015 Nov 12; 11(10):1635-45. PubMed ID: 26327145
    [Abstract] [Full Text] [Related]

  • 8. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun 12; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 9. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb 12; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

  • 10. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008 Feb 12; 9(3):197-202. PubMed ID: 18457473
    [Abstract] [Full Text] [Related]

  • 11. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
    Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Rönnelid J, Malmström V, Bengtsson AA, Gunnarsson I.
    Autoimmun Rev; 2017 Apr 12; 16(4):343-351. PubMed ID: 28216072
    [Abstract] [Full Text] [Related]

  • 12. Update on belimumab for the management of systemic lupus erythematosus.
    Lutalo PM, D'Cruz DP.
    Expert Opin Biol Ther; 2014 Nov 12; 14(11):1701-8. PubMed ID: 25303323
    [Abstract] [Full Text] [Related]

  • 13. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM, BLISS-52 and -76 Study Groups.
    Lupus; 2013 Jan 12; 22(1):63-72. PubMed ID: 23263865
    [Abstract] [Full Text] [Related]

  • 14. Belimumab for the treatment of pediatric patients with lupus nephritis.
    Stohl W, Kwok A.
    Expert Opin Biol Ther; 2023 Mar 12; 23(3):243-251. PubMed ID: 36750049
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group.
    Lancet; 2011 Feb 26; 377(9767):721-31. PubMed ID: 21296403
    [Abstract] [Full Text] [Related]

  • 16. The Role of Belimumab in Systemic Lupus Erythematosis: A Systematic Review.
    Joy A, Muralidharan A, Alfaraj M, Shantharam D, Cherukuri ASS, Muthukumar A.
    Cureus; 2022 Jun 26; 14(6):e25887. PubMed ID: 35844357
    [Abstract] [Full Text] [Related]

  • 17. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, Gatto M, Piantoni S, Nalotto L, Franceschini F, Larosa M, Fredi M, Punzi L, Tincani A, Doria A.
    Arthritis Care Res (Hoboken); 2017 Jan 26; 69(1):115-123. PubMed ID: 27390293
    [Abstract] [Full Text] [Related]

  • 18. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
    Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, Belimumab Study Group.
    Arthritis Res Ther; 2008 Jan 26; 10(5):R109. PubMed ID: 18786258
    [Abstract] [Full Text] [Related]

  • 19. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
    Deng WP.
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct 15; 23(10):1069-1074. PubMed ID: 34719425
    [Abstract] [Full Text] [Related]

  • 20. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient).
    Binda V, Trezzi B, Del Papa N, Beretta L, Frontini G, Porata G, Fabbrini P, Pozzi MR, Messa P, Sinico RA, Moroni G.
    J Nephrol; 2020 Oct 15; 33(5):1019-1025. PubMed ID: 32002799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.